Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03206099 · ClinicalTrials.gov registry record
NIAID Centralized Sequencing Protocol
A clinical trial of Primary Immunodeficiency and Atopy, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- 20,000
- Enrollment target
- 2
- Study locations
NCT03206099 is a study of Primary Immunodeficiency and Atopy that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 20,000 participants, above the 840-participant average among 4 other Primary Immunodeficiency trials with a reported enrollment target (2281% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT03206099, a study of Primary Immunodeficiency and Atopy, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- 20,000 participants
- Enrollment target
- 2
- Study locations
Study Summary
Background: Genetic testing called "sequencing" helps researchers look at DNA. Genes are made of DNA and are the instructions for our bodies to function. We all have thousands of genes. DNA variants are differences in genes between two people. We all have lots of variants. Most are harmless and some cause differences like blue or brown eyes. A few variants can cause health problems. Objective: To understand the genetics of immune disorders various health conditions, as well as outcomes of clinical genomics and genetic counseling services performed under this protocol. Eligibility: Participants in other NIH human subjects research protocols - either at the NIH Clinical Center (CC) or at Children s National Health System (CNHS) - (aged 0-99 years), and, in select cases, their biological relatives Design: Researchers will study participant s DNA extracted from blood, saliva, or another tissue sample, including previously collected samples we may have stored at the NIH. Researchers will look at participant s DNA in great detail. We are looking for differences in the DNA sequence or structure between participants and other people. Participants will receive results that: * Are important to their health * Have been confirmed in a clinical lab * Suggest that they could be at risk for serious disease that may affect your current or future medical management. Some genetic information we return to participants may be of uncertain importance. If genetic test results are unrelated to the participant s NIH evaluations, then we will not typically report: * Normal variants * Information about progressive, fatal conditions that have no effective treatment * Carrier status (conditions you don t have but could pass on) The samples and data will be saved for future research. Personal data will be kept as private as possible. If future studies need new information, participants may be contacted.
Conditions Studied
Study Locations (2)
District of Columbia
- Children's National Health System - Washington D.C.
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,000 participants |
| Start Date | 2017-07-31 |
| Est. Completion | 2029-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03206099
The ClinicalTrials.gov registry entry for NCT03206099 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 840-participant average among 4 other Primary Immunodeficiency trials with a reported enrollment target (2281% higher). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Primary Immunodeficiency appearing as the primary indexed condition, and to 0 interventions.
NCT03206099 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, Maryland.
Frequently Asked Questions
What is clinical trial NCT03206099 about?
NCT03206099 is a clinical study titled "NIAID Centralized Sequencing Protocol". Background: Genetic testing called "sequencing" helps researchers look at DNA. Genes are made of DNA and are the instructions for our bodies to function. We all have thousands of genes. DNA variants are differences in genes between two people. We all have lots of variants. Most are harmless and som...
What is the current status of trial NCT03206099?
This trial is currently recruiting. The enrollment target is 20,000 participants. The study started on 2017-07-31. Estimated completion is 2029-12-31.
What conditions does trial NCT03206099 study?
This clinical trial studies the following conditions: Primary Immunodeficiency, Atopy, Autoimmunity, Autoinflammation.
Who is sponsoring clinical trial NCT03206099?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03206099 being conducted?
This trial has 2 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Immunodeficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
RECRUITING
-
Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies
RECRUITING
-
An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)
RECRUITING · Phase 4
-
Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.